Equity
Treasury Stock
Regeneron Pharmaceuticals Treasury Stock increased by 4.3% to $19.41B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 19.7%, from $16.22B to $19.41B. Over 4 years (FY 2021 to FY 2025), Treasury Stock shows an upward trend with a 22.5% CAGR.
Analysis
StatementBalance Sheet Statement
SectionEquity
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ4 2014
Last reportedQ1 2026
How to read this metric
An increase indicates active share buybacks, which can signal management's confidence in the stock or an effort to return capital to shareholders.
Detailed definition
Treasury stock represents the cost of shares that a company has repurchased from the open market and holds in its own tr...
Peer comparison
Standard across all public companies; peers in the pharmaceutical sector often use buybacks to manage earnings per share.
Metric ID:
treasury_stockHistorical Data
15 periods
| Q4 '21 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $8.26B | $10.35B | $11.05B | $11.77B | $12.27B | $12.56B | $12.86B | $13.46B | $14.19B | $15.17B | $16.22B | $17.28B | $17.94B | $18.61B | $19.41B |
| QoQ Change | — | +25.3% | +6.7% | +6.5% | +4.3% | +2.4% | +2.4% | +4.7% | +5.5% | +6.9% | +6.9% | +6.6% | +3.8% | +3.7% | +4.3% |
| YoY Change | — | +25.3% | — | — | — | +21.3% | +16.4% | +14.4% | +15.7% | +20.8% | +26.1% | +28.5% | +26.4% | +22.7% | +19.7% |
Range$8.26B – $19.41B
CAGR+27.7%
Avg YoY Growth+21.6%
Median YoY Growth+21.3%
Current Streak14+ quarters growth
Treasury Stock at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's treasury stock?
- Regeneron Pharmaceuticals (REGN) reported treasury stock of $19.41B in Q1 2026.
- How has Regeneron Pharmaceuticals's treasury stock changed year-over-year?
- Regeneron Pharmaceuticals's treasury stock increased by 19.7% year-over-year, from $16.22B to $19.41B.
- What is the long-term trend for Regeneron Pharmaceuticals's treasury stock?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's treasury stock has grown at a 22.5% compound annual growth rate (CAGR), from $8.26B to $18.61B.
- What does treasury stock mean?
- The value of shares a company has bought back from the market.